Advertisement

Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate

      Highlights

      • Atherosclerosis imaging has been supported and opposed as a method to improve screening.
      • Imaging has been extensively used for atherosclerosis regression studies.
      • Should future clinical drug trials be based on imaging?

      Abstract

      Atherosclerosis imaging has been the focus of intense debate and research for several decades. Among its primary applications are risk stratification of asymptomatic individuals and follow-up of atherosclerosis progression under a variety of treatments designed to retard or regress the development of arterial disease. Although endorsed and supported by many, this approach has been fiercely opposed by several key opinion leaders over the years. Similarly, regulatory agencies have raised a number of objections to resist the approval of new drugs and devices based on surrogate imaging markers. However, there is a large body of evidence in the medical literature that shows that risk stratification is improved with implementation of atherosclerosis imaging. Additionally, numerous lipid-modifying agents have been tested as far as their ability to affect progression of atherosclerosis, and in many cases the information obtained with imaging was in line with the outcome of subsequent clinical trials. This pros-and-cons debate was staged to bring up in a fun and provoking way the main arguments in favour or against the application of atherosclerosis imaging in the main settings described above.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjamin E.J.
        • Blaha M.J.
        • Chiuve S.E.
        • Cushman M.
        • Das S.R.
        • Deo R.
        • et al.
        American Heart Association statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association.
        Circulation. 2017; 135 (Erratum in: Circulation. 2017;135:e646): e146-e603
        • Yusuf S.
        • Lonn E.
        • Pais P.
        • Bosch J.
        • López-Jaramillo P.
        • Zhu J.
        • et al.
        HOPE-3 investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease.
        N. Engl. J. Med. 2016; 374: 2032-2043
        • Polonsky T.S.
        • McClelland R.L.
        • Jorgensen N.W.
        • Bild D.E.
        • Burke G.L.
        • Guerci A.D.
        • et al.
        Coronary artery calcium score and risk classification for coronary heart disease prediction.
        JAMA. 2010; 303: 1610-1616
        • Erbel R.
        • Möhlenkamp S.
        • Moebus S.
        • Schmermund A.
        • Lehmann N.
        • Stang A.
        • et al.
        Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study.
        J. Am. Coll. Cardiol. 2010; 56: 1397-1406
        • Hecht H.S.
        Coronary artery calcium scanning: past, present, and future.
        JACC Cardiovasc Imaging. 2015; 8: 579-596
        • Blaha M.J.
        • Budoff M.J.
        • DeFilippis A.P.
        • Blankstein R.
        • Rivera J.J.
        • Agatston A.
        • et al.
        Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.
        Lancet. 2011; 378: 684-692
        • Rozanski A.
        • Gransar H.
        • Shaw L.J.
        • Kim J.
        • Miranda-Peats L.
        • Wong N.D.
        • et al.
        Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial.
        J. Am. Coll. Cardiol. 2011; 57: 1622-1632
        • Roberts E.T.
        • Horne A.
        • Martin S.S.
        • Blaha M.J.
        • Blankstein R.
        • Budoff M.J.
        • et al.
        Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).
        PLoS One. 2015; 10: e0116377
        • Blaha M.
        • Budoff M.J.
        • Shaw L.J.
        • Khosa F.
        • Rumberger J.A.
        • Berman D.
        • et al.
        Absence of coronary artery calcification and all-cause mortality.
        JACC Cardiovasc Imaging. 2009; 2: 692-700
        • Hecht H.S.
        • Achenbach S.
        • Kondo T.
        • Narula J.
        High-risk plaque features on coronary ct angiography.
        JACC Cardiovasc Imaging. 2015; 8: 1336-1339
        • Kavousi M.
        • Desai C.S.
        • Ayers C.
        • Blumenthal R.S.
        • Budoff M.J.
        • Mahabadi A.A.
        • et al.
        Prevalence and prognostic implications of coronary artery calcification in low-risk women: a Meta-analysis.
        JAMA. 2016; 316: 2126-2134
        • Möhlenkamp S.
        • Lehmann N.
        • Greenland P.
        • Moebus S.
        • Kälsch H.
        • Schmermund A.
        • et al.
        Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy.
        Atherosclerosis. 2011; 215: 229-236
        • Brown G.
        • Albers J.J.
        • Fisher L.D.
        • Schaefer S.M.
        • Lin J.T.
        • Kaplan C.
        • Zhao X.Q.
        • et al.
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N. Engl. J. Med. 1990; 323: 1289-1298
        • Watts G.F.
        • Lewis B.
        • Brunt J.N.
        • Lewis E.S.
        • Coltart D.J.
        • Smith L.D.
        • et al.
        Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS).
        Lancet. 1992; 339: 563-569
        • Nicholls S.J.
        • Hsu A.
        • Wolski K.
        • Hu B.
        • Bayturan O.
        • Lavoie A.
        • Uno K.
        • et al.
        Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome.
        J. Am. Coll. Cardiol. 2010; 55: 2399-2407
        • Budoff M.J.
        • Hokanson J.E.
        • Nasir K.
        • Shaw L.J.
        • Kinney G.L.
        • Chow D.
        • et al.
        Progression of coronary artery calcium predicts all-cause mortality.
        JACC Cardiovasc Imaging. 2010; 3: 1229-1236
        • Henein M.
        • Granåsen G.
        • Wiklund U.
        • Schmermund A.
        • Guerci A.
        • Erbel R.
        • et al.
        High dose and long-term statin therapy accelerate coronary artery calcification.
        Int. J. Cardiol. 2015; 184: 581-586
        • Shin S.
        • Park H.B.
        • Chang H.J.
        • Arsanjani R.
        • Min J.K.
        • Kim Y.J.
        • et al.
        Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study.
        JACC Cardiovasc Imaging. 2017; 10: 437-446
        • Wannarong T.
        • Parraga G.
        • Buchanan D.
        • Fenster A.
        • House A.A.
        • Hackam D.G.
        • et al.
        Progression of carotid plaque volume predicts cardiovascular events.
        Stroke. 2013; 44: 1859-1865
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • Honarpour N.
        • Wiviott S.D.
        • Murphy S.A.
        • et al.
        FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722
        • Nicholls S.J.
        • Puri R.
        • Anderson T.
        • Ballantyne C.M.
        • Cho L.
        • Kastelein J.J.
        • et al.
        Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.
        JAMA. 2016; 316: 2373-2384
        • Crouse 3rd, J.R.
        • Raichlen J.S.
        • Riley W.A.
        • Evans G.W.
        • Palmer M.K.
        • O'Leary D.H.
        • et al.
        METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
        JAMA. 2007; 297: 1344-1353
        • Nissen S.E.
        • Nicholls S.J.
        • Sipahi I.
        • Libby P.
        • Raichlen J.S.
        • Ballantyne C.M.
        • et al.
        ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
        JAMA. 2006; 295: 1556-1565
        • Nissen S.E.
        • Tardif J.C.
        • Nicholls S.J.
        • Revkin J.H.
        • Shear C.L.
        • Duggan W.T.
        • et al.
        Effect of torcetrapib on the progression of coronary atherosclerosis.
        N. Engl. J. Med. 2007; 356 (Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P): 1304-1316
        • Raggi P.
        • Baldassarre D.
        • Day S.
        • de Groot E.
        • Fayad Z.A.
        Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development.
        Atherosclerosis. 2016; 251: 476-482
        • Selby K.
        • Nanchen D.
        • Auer R.
        • Gencer B.
        • Raber L.
        • Klingenberg R.
        • et al.
        Low statin use in adults hospitalized with acute coronary syndrome.
        Prev. Med. 2015; 77: 131-136
        • Goff Jr., D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • Coady S.
        • D'Agostino R.B.
        • Gibbons R.
        • et al.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the american college of cardiology/american heart association task force on practice guidelines.
        Circulation. 2014; 129: S49-S73
        • Piepoli M.F.
        • Hoes A.W.
        • Agewall S.
        • Albus C.
        • Brotons C.
        • Catapano A.L.
        • et al.
        2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
        Eur. Heart J. 2016; 37: 2315-2381
        • Greenland P.
        • Alpert J.S.
        • Beller G.A.
        • Benjamin E.J.
        • Budoff M.J.
        • Fayad Z.A.
        • et al.
        2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the american college of cardiology foundation/american heart association task force on practice guidelines.
        Circulation. 2010; 122: e584-e636
        • Yeboah J.
        • Young R.
        • McClelland R.L.
        • Delaney J.C.
        • Polonsky T.S.
        • Dawood F.Z.
        • et al.
        Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment.
        J. Am. Coll. Cardiol. 2016; 67: 139-147
        • Blaha M.J.
        • Cainzos-Achirica M.
        • Greenland P.
        • McEvoy J.W.
        • Blankstein R.
        • Budoff M.J.
        • et al.
        Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA).
        Circulation. 2016; 133: 849-858
        • Nasir K.
        • Bittencourt M.S.
        • Blaha M.J.
        • Blankstein R.
        • Agatson A.S.
        • Rivera J.J.
        • et al.
        Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
        J. Am. Coll. Cardiol. 2015; 66: 1657-1668
        • Carr J.J.
        • Jacobs Jr., D.R.
        • Terry J.G.
        • Shay C.M.
        • Sidney S.
        • Liu K.
        • et al.
        Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death.
        JAMA Cardiol. 2017; 2: 391-399
        • de Weerd M.
        • Greving J.P.
        • Hedblad B.
        • Lorenz M.W.
        • Mathiesen E.B.
        • O'Leary D.H.
        • et al.
        Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis.
        Stroke. 2010; 41: 1294-1297
        • Jonas D.E.
        • Feltner C.
        • Amick H.R.
        • Sheridan S.
        • Zheng Z.J.
        • Watford D.J.
        • et al.
        Screening for asymptomatic carotid artery stenosis: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.
        Ann. Intern Med. 2014; 161: 336-346
        • Keyhani S.
        • Cheng E.M.
        • Naseri A.
        • Halm E.A.
        • Williams L.S.
        • Johanning J.
        • et al.
        Common reasons that asymptomatic patients who are 65 years and older receive carotid imaging.
        JAMA Intern Med. 2016; 176: 626-633
        • Kalia N.K.
        • Miller L.G.
        • Nasir K.
        • Blumenthal R.S.
        • Agrawal N.
        • Budoff M.J.
        Visualizing coronary calcium is associated with improvements in adherence to statin therapy.
        Atherosclerosis. 2006; 185: 394-399
        • Orakzai R.H.
        • Nasir K.
        • Orakzai S.H.
        • Kalia N.
        • Gopal A.
        • Musunuru K.
        • et al.
        Effect of patient visualization of coronary calcium by electron beam computed tomography on changes in beneficial lifestyle behaviors.
        Am. J. Cardiol. 2008; 101: 999-1002
        • O'Malley P.G.
        • Feuerstein I.M.
        • Taylor A.J.
        Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial.
        JAMA. 2003; 289: 2215-2223
        • Rodondi N.
        • Collet T.H.
        • Nanchen D.
        • Locatelli I.
        • Depairon M.
        • Aujesky D.
        • et al.
        Impact of carotid plaque screening on smoking cessation and other cardiovascular risk factors: a randomized controlled trial.
        Arch. Intern Med. 2012; 172: 344-352
        • Pletcher M.J.
        • Pignone M.
        • Earnshaw S.
        • McDade C.
        • Phillips K.A.
        • Auer R.
        • et al.
        Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.
        Circ. Cardiovasc Qual. Outcomes. 2014; 7: 276-284
        • Raggi P.
        • Callister T.Q.
        • Shaw L.J.
        Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy.
        Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1272-1277
        • Libby P.
        Mechanisms of acute coronary syndromes and their implications for therapy.
        N. Engl. J. Med. 2013; 368: 2004-2013
        • Chou R.
        • Dana T.
        • Blazina I.
        • Daeges M.
        • Jeanne T.L.
        Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force.
        JAMA. 2016; 316: 2008-2024
        • Nicholls S.J.
        • Ballantyne C.M.
        • Barter P.J.
        • Chapman M.J.
        • Erbel R.M.
        • Libby P.
        • et al.
        Effect of two intensive statin regimens on progression of coronary disease.
        N. Engl. J. Med. 2011; 365: 2078-2087
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • Bruckert E.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies.
        Eur. Heart J. 24 Apr 2017; (A consensus statement from the European Atherosclerosis Society Consensus Panel) ([Epub ahead of print] (article still reported on PubMed as Epub status))https://doi.org/10.1093/eurheartj/ehx144
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397
        • Libby P.
        • Aikawa M.
        Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.
        Nat. Med. 2002; 8: 1257-1262